Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Benznidazole/Pyronaridine - Collaborations Pharmaceuticals

Next Previous
Drug Profile

Benznidazole/Pyronaridine - Collaborations Pharmaceuticals

Alternative Names: Pyronaridine/benznidazole - Collaborations Pharmaceuticals

Latest Information Update: 09 Mar 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Collaborations Pharmaceuticals
  • Class Acetamides; Acridines; Antimalarials; Antiprotozoals; Imidazoles; Naphthyridines; Small molecules
  • Mechanism of Action Free radical stimulants; Hemozoin inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chagas disease
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Chagas disease

Most Recent Events

  • 22 Feb 2022 Benznidazole/Pyronaridine - Collaborations Pharmaceuticals is available for licensing as of 07 Feb 2022. https://www.collaborationspharma.com/pipeline
  • 07 Feb 2022 Preclinical trials in Chagas disease in USA (unspecified route) (Collaborations Pharmaceuticals pipeline, February 2022)
  • 05 Nov 2020 Benznidazole/Pyronaridine - Collaborations Pharmaceuticals receives Orphan Drug status for Chagas disease in China

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top